Amphista Therapeutics Limited

Amphista Therapeutics Limited is a pioneering biopharmaceutical company based in the United Kingdom that stands at the forefront of targeted protein degradation (TPD). The company's slogan, "A new approach to targeted protein degradation to bring life-changing medicines to patients," underscores its commitment to transforming patient outcomes through innovative treatments.

Founded in 2017 as a spin-out from Advent Life Sciences, Amphista builds upon the pioneering research of Professor Alessio Ciulli of the University of Dundee, a luminary in the TPD arena. The company is carving out its niche by advancing beyond traditional degradation mechanisms to tackle diseases with minimal current treatment options.

Amphista's most recent funding round was a Series B investment received on December 13, 2022, with backing from the Dementia Discovery Fund. As it continues to evolve, Amphista stands out as a promising player in the Biopharma and Biotechnology industries, worthy of attention from investors looking for groundbreaking advancements in disease treatment.